Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-490 alone or with dexamethasone in relapsed/refractory multiple myeloma
CTR20223160Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Mar 2023
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ICP-490 in multiple myeloma (MM), sponsored by Innovent Biologics. Started Mar 2023; status: active.
02
Drugs
ICP-490
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20223160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223160.